iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to ElektaGlobeNewsWire • 10/23/23
Health Canada Grants Device License for iCAD's ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year AssessmentGlobeNewsWire • 08/16/23
iCAD Signs Strategic Commercial Agreement with Radiology Partners, the Nation's Largest Radiology PracticeGlobeNewsWire • 07/18/23
iCAD's “ProFound Insights, ProFound Impact” Webinar Series to Feature Cleveland ClinicGlobeNewsWire • 07/12/23
iCAD Offers ROI Analysis Based on Real-World Results from its ProFound Breast AI Suite at AHRA Annual MeetingGlobeNewsWire • 07/10/23
iCAD's ProFound AI Breast Suite Wins U.S. General Services Administration's AI Healthcare Challenge AwardGlobeNewsWire • 05/18/23